주요 효모균과 사상형 진균의 항진균제 내성현황 = Antifungal Resistance in Yeasts and Filamentous Fungi

다국어 초록 (Multilingual Abstract)

The incidence of invasive fungal infection has increased worldwide along with the increasing population of high risk patients. Recently developed antifungal agents, such as second-generation triazoles and echinocandins, provide the potential to improve therapeutic options against invasive fungal infections. However, treatment of invasive fungal infections has been hampered by both intrinsic and acquired resistance to antifungal agents among many fungal pathogens. A better understanding of the clinical impact of antifungal resistance is important for selecting the proper antifungal agent in patients with systemic fungal infections. This article reviews the current situation with regard to intrinsic and acquired resistance of clinically significant yeasts and filamentous fungi against currently available antifungal agents.

참고문헌 (Reference)

1 신종희, "한국인의 임상분리 아스페르길루스 균주에 대한 보리코나졸의 생체외 감수성" 대한의진균학회1 9 (9): 166-173, 2004

2 최현우, "칸디다 균종의 Caspofungin과 Micafungin에 대한 생체 외 감수성 성적" 대한진단검사의학회 26 (26): 275-281, 2006

3 이진솔, "임상검체에서 분리된 아스페르길루스 균주의 Echinocandin에 대한 생체 외 감수성" 대한감염학회 39 (39): 151-158, 2007

4 Kim SH, "The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study" 47 : 296-304, 2009

5 Espinel-Ingroff A, "Susceptibility test methods: yeasts and filamentous fingi in Manual of clinical microbiology" ASM Press 1972-, 2008

6 이진솔, "Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea" 연세대학교의과대학 48 (48): 779-786, 2007

7 Sanglard D, "Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences" 2 : 73-85, 2002

8 Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi.2nd ed. Approved standard M38-A2, Villanova, Pa., Clinical and Laboratory Standards Institute, 2008"

9 Shao PL, "Recent advances and challenges in the treatment of invasive fungal infections" 30 : 487-495, 2007

10 Pfaller MA, "Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus" 42 : 4419-4431, 2004

11 Stevens DA, "Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations" 48 : 3407-3411, 2004

12 Espinel-Ingroff A, "Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi" 25 : 101-106, 2008

13 Sanguinetti M, "Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance" 49 : 668-679, 2005

14 Pfaller MA, "Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing" 19 : 435-447, 2006

15 Messer SA, "International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003)" 1782-7,2006 44 : 1782-1787, 2006

16 Siwek GT, "Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis" 55 : 209-212, 2006

17 Lass-Flörl C, "In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis" 42 : 497-502, 1998

18 Pappas PG, "Guidelines for treatment of candidiasis" 38 : 161-189, 2004

19 Pfaller MA, "Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing" 45 : 1735-1745, 2007

20 Pfaller MA, "Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002" 42 : 3142-3146, 2004

21 Stevens DA, "Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin" 50 : 3160-3161, 2006

22 Pfaller MA, "Epidemiology of invasive candidiasis: a persistent public health problem" 20 : 133-163, 2007

23 Cheung C, "Development of candidemia on caspofungin therapy: a case report" 34 : 345-348, 2006

24 Arikan S, "Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates" 43 : 107-111, 2002

25 Shin JH, "Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia" 45 : 2385-2391, 2007

26 Kim MN, "Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features" 48 : e57-61, 2009

27 박지영, "CLSI 액체배지 미량희석법, Etest 및 Minimum Fungicidal Concentration 검사에 의한 국내 혈액에서 분리된 효모균의 시험관 내 Amphotericin B 내성 성적" 대한진단검사의학회 28 (28): 346-352, 2008

28 Matsue K, "Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin" 42 : 753-757, 2006

29 Balashov SV, "Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1" 50 : 2058-2063, 2006

30 Balajee SA, "Aspergillus lentulus sp. nov., a new sibling species of A" 4 : 625-632, 2005

31 Kanafani ZA, "Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact" 46 : 120-128, 2008

32 Arikan S, "Antifungal agents in Manual of clinical microbiology" ASM Press 1949-, 2008

33 Pfaller MA, "Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000" 46 : 1032-1037, 2002